Safe to stop immunotherapy at two years in advanced NSCLC: study
Results should reassure patients with progression-free advanced disease, say doctors.
Patients who are progression-free on immunotherapy for advanced or metastatic lung cancer can safely discontinue therapy after two years, US oncologists report.
Despite doctors’ “substantial hesitation” to cease immune checkpoint inhibitor (ICI) therapy, the researchers found no overall survival benefit from indefinite treatment.
